Safety and Efficacy of Camrelizumab (Anti-PD-1 Antibody) in Recurrent HCC After Liver Transplantation
Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
This is a prospective clinical study to investigate the safety and efficacy of anti-PD-1
immunotherapy (Camrelizumab) in patients with recurrent hepatocellular carcinoma (HCC) after
liver transplantation. All of the enrolled patients have a background of liver
transplantation for HCC. Due to the tumor recurrence, patients are not suitable for curative
surgical resection, and targeted therapy provides poor therapeutic effect, leading to tumor
progression or intolerance. Before immunotherapy, the PD-L1 expression was confirmed negative
in the graft liver by immunohistochemistry, and patients continued targeted therapy as part
of a combined antitumor regimen. In addition, the immunosuppression schedule is also reduced
to a low level.